Silo Pharma (NASDAQ: SILO) announced that its wholly owned managed AI agent subsidiary, QwikAgents, has expanded its platform with support for customer-supplied NVIDIA API keys and the addition of Hermes agent runtime. The move adds NVIDIA as the fifth supported bring-your-own-key provider, joining Anthropic, OpenAI, Google and DeepSeek. Customers can now use their own NVIDIA API keys to access NVIDIA Nemotron models, while Hermes gives them an alternative to the existing OpenClaw runtime when creating an AI agent.
Both runtimes operate on QwikAgents infrastructure, which includes managed hosting, persistent memory, model routing and dedicated compute. For enterprises building AI agents, the ability to bring their own API keys can reduce costs and simplify procurement, as they can leverage existing NVIDIA agreements rather than purchasing tokens through a third party. The addition of Hermes as a runtime option also gives developers more flexibility to match the runtime to their specific workload requirements, whether that means optimizing for performance, compatibility or cost.
The announcement matters because it signals Silo Pharma’s continued investment in its AI subsidiary, which sits alongside its developmental-stage biopharmaceutical programs. Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company’s portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its research is conducted in collaboration with leading universities and laboratories.
By expanding QwikAgents’ capabilities, Silo Pharma is positioning the subsidiary to compete in the rapidly growing market for managed AI agent infrastructure. The bring-your-own-key model has become increasingly popular among enterprises that want to maintain control over their AI spending and data governance. With NVIDIA now on the list, QwikAgents can appeal to organizations already using NVIDIA’s AI stack. The full press release is available at https://ibn.fm/AXpqr.
Investors and industry observers can find the latest news and updates relating to SILO in the company’s newsroom at https://ibn.fm/SILO. The announcement was distributed through AINewsWire, a specialized communications platform focused on artificial intelligence advancements. AINewsWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services.
The expansion of QwikAgents comes as demand for AI agent platforms continues to rise, with enterprises seeking managed solutions that offer choice in models and runtimes. By supporting multiple providers and runtimes, QwikAgents aims to differentiate itself in a crowded field. For Silo Pharma, the success of its AI subsidiary could provide a valuable diversification beyond its biopharmaceutical pipeline.
